Abstract
Bladder cancer (BCa) is the fourth most common cancer in men (Larré et al. in Eur Urol 63(6):1049–1058, 2013). Survival from the disease has not improved over the last quarter century. Bladder cancer is 1 of the 10 most frequently diagnosed types of cancer. Screening could identify high-grade bladder cancer at earlier stages, when it may be more easily and effectively treated Population-based screening theoretically provides the best opportunity to improve the outcomes of aggressive BCa (Larré et al. in Eur Urol 63(6):1049–1058, 2013).This chapter covers assessments and diagnostic pathways in NMIBC .
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bonberg N, Taeger D, Gawrych K, Johnen G, Banek S, Schwentner C, Sievert KD, Wellhäußer H, Kluckert M, Leng G, Nasterlack M, Stenzl A, Behrens T, Brüning T, Pesch B; UroScreen Study Group. Chromosomal instability and bladder cancer: the UroVysionn(™) test in the UroScreen study. BJU Int. 2013;112(4):E372–82.
Cassidy LD, Marsh GM, Talbott EO, Kelsey SF. Initial and continued adherence with bladder cancer screening in an occupationally exposed cohort. J Occup Environ Med. 2011;53(4):455–6.
Chou R, Dana T. Screening adults for bladder cancer: a review of the evidence for the U.S. preventive services task force. Ann Intern Med. 2010;153(7):461–8.
Larré S, Catto JW, Cookson MS, Messing EM, Shariat SF, Soloway MS, Svatek RS, Lotan Y, Zlotta AR, Grossman HB. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol. 2013;63(6):1049–58.
Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10(6):311–22.
Pesch B, Nasterlack M, Eberle F, Bonberg N, Taeger D, Leng G, Feil G, Johnen G, Ickstadt K, Kluckert M, Wellhäusser H, Stenzl A, Brüning T; UroScreen Group. The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU Int. 2011;108(4):546–52.
Schmitz-Dräger BJ, Droller M, Lokeshwar VB, Lotan Y, Hudson MA, van Rhijn BW, Marberger MJ, Fradet Y, Hemstreet GP, Malmstrom PU, Ogawa O, Karakiewicz PI, Shariat SF. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int. 2015;94(1):1–24. https://doi.org/10.1159/000369357 Epub 2014 Dec 10.
Vickers AJ, Bennette C, Kibel AS, Black A, Izmirlian G, Stephenson AJ, Bochner B. Who should be included in a clinical trial of screening for bladder cancer? A decision analysis of data from the prostate, lung, colorectal and ovarian cancer screening trial. Cancer. 2013;119(1):143–9.
Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics. 2014;32(11):1093–104.
Zlotta AR, Roumeguere T, Kuk C, Alkhateeb S, Rorive S, Lemy A, van der Kwast TH, Fleshner NE, Jewett MA, Finelli A, Schulman C, Lotan Y, Shariat SF, Nortier J. Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. Eur Urol. 2011;59(6):1026–31.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Goonewardene, S.S., Persad, R., Motiwala, H., Albala, D. (2020). Bladder Cancer—Diagnostic Pathways. In: Management of Non-Muscle Invasive Bladder Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-28646-0_12
Download citation
DOI: https://doi.org/10.1007/978-3-030-28646-0_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-28645-3
Online ISBN: 978-3-030-28646-0
eBook Packages: MedicineMedicine (R0)